Christopher Cao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Christopher Cao has a total of 136 co-authors. Here are the top co-authors by number of shared publications:
- Tristan Dongbo Yan
Department of Cardiothoracic Surgery, Royal Prince Alfred Hospital, Sydney, Australia
23 shared publications David H. Tian
Collaborative Research Group, Macquarie University, Sydney, Australia
14 shared publicationsHugh Wolfenden
8 shared publicationsPraveen Indraratna
The Collaborative Research (CORE) Group, Macquarie University, Sydney, Australia; Department of Cardiology, St George Hospital, Sydney, Australia
8 shared publicationsSu C. Ang
Systematic Review Unit, Collaborative Research (CORE) Group, Macquarie University, Sydney, Australia
8 shared publicationsDavid Chandrakumar
The Systematic Review Unit, The Collaborative Research (CORE) Group, Macquarie University, Sydney, Australia
6 shared publications
Latest Publications
- Open Access
- 2 November 2026
- Published by Springer Nature in General Thoracic and Cardiovascular Surgery
- p. 1-6
Coexistent tracheal bronchus and azygos lobe: surgical planning and operative technique for robotic-assisted right upper lobectomy
Tracheal bronchus and azygos lobe are individually uncommon congenital anomalies arising from independent embryological mechanisms. Their simultaneous occurrence is exceptionally rare, with fewer than five cases identifiable in the published literature. We report an adult patient in whom a displaced apical segmental bronchus arising directly from the tracheal wall, a bifid right upper lobe bronchus comprising only the anterior and posterior segmental bronchi, and an associated azygos lobe. Elective robotic-assisted right upper lobectomy was undertaken for a biopsy proven primary lung cancer. Final histopathology confirmed grade 2 adenocarcinoma with clear surgical margins without lymph node involvement. Preoperative three-dimensional reconstruction was helpful for surgical planning and we describe the operative principles required to safely manage this unusual anatomical combination.
- 2 November 2026
- Published by Springer Nature in General Thoracic and Cardiovascular Surgery
- p. 1-6
Open AccessCoexistent tracheal bronchus and azygos lobe: surgical planning and operative technique for robotic-assisted right upper lobectomy
Tracheal bronchus and azygos lobe are individually uncommon congenital anomalies arising from independent embryological mechanisms. Their simultaneous occurrence is exceptionally rare, with fewer than five cases identifiable in the published literature. We report an adult patient in whom a displaced apical segmental bronchus arising directly from the tracheal wall, a bifid right upper lobe bronchus comprising only the anterior and posterior segmental bronchi, and an associated azygos lobe. Elective robotic-assisted right upper lobectomy was undertaken for a biopsy proven primary lung cancer. Final histopathology confirmed grade 2 adenocarcinoma with clear surgical margins without lymph node involvement. Preoperative three-dimensional reconstruction was helpful for surgical planning and we describe the operative principles required to safely manage this unusual anatomical combination.
- 20 September 2024
- Published by Elsevier in Heart, Lung and Circulation
- Vol. 33 (11) , 1600-1604
Indocyanine Green (ICG): A Versatile Tool in Enhancing Precision in Minimally Invasive Thoracic Surgery
- 20 September 2024
- Published by Elsevier in Heart, Lung and Circulation
- Vol. 33 (11) , 1600-1604
Indocyanine Green (ICG): A Versatile Tool in Enhancing Precision in Minimally Invasive Thoracic Surgery
- 7 December 2023
- Published by Elsevier in Heart, Lung and Circulation
- Vol. 33 (1) , 86-91
Robotic Anatomical Pulmonary Resections: An Australian Experience
- 7 December 2023
- Published by Elsevier in Heart, Lung and Circulation
- Vol. 33 (1) , 86-91
Robotic Anatomical Pulmonary Resections: An Australian Experience
- Open Access
- 1 October 2023
- Published by AME Publishing Company in AME Clinical Trials Review
- Vol. 1, 6
Neoadjuvant immunotherapy for resectable non-small cell lung cancer—what lies ahead
Neoadjuvant immunotherapy for resectable non-small cell lung cancer—what lies ahead
- 1 October 2023
- Published by AME Publishing Company in AME Clinical Trials Review
- Vol. 1, 6
Open AccessNeoadjuvant immunotherapy for resectable non-small cell lung cancer—what lies ahead
Neoadjuvant immunotherapy for resectable non-small cell lung cancer—what lies ahead
- 20 February 2023
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 63 (4)
Consensus on technical procedures for simulation-based training in thoracic surgery: an international needs assessment
OBJECTIVES: To identify and prioritize technical procedures for simulation-based training to be integrated into the thoracic surgical curriculum. METHODS: A 3-round Delphi survey was conducted from February 2022 to June 2022 among 34 key opinion leaders in thoracic surgery from 14 countries worldwide. The 1st round was a brainstorming phase to identify technical procedures that a newly qualified thoracic surgeon should be able to perform. All the suggested procedures were categorized, qualitatively analysed and sent to the 2nd round. The second round investigated: the frequency of the identified procedure at each institution, the number of thoracic surgeons that should be able to perform these procedures, the degree of risk to the patient if the procedure is performed by a non-competent thoracic surgeon and the feasibility of simulation-based education. In the 3rd round, elimination and re-ranking of the procedures from the 2nd round were performed. RESULTS: Response rates in the 3 iterative rounds were 80% (28 out of 34), 89% (25 out of 28) and 100% (25 out of 25) in the 1st, 2nd and 3rd round, respectively. Seventeen technical procedures were included for simulation-based training in the final prioritized list. The top 5 procedures were Video-Assisted Thoracoscopic Surgery (VATS) lobectomy, VATS segmentectomy, VATS mediastinal lymph node dissection, diagnostic flexible bronchoscopy and robotic-assisted thoracic surgery port placement, robotic-assisted thoracic surgery docking and undocking. CONCLUSIONS: The prioritized list of procedures represents a consensus of key thoracic surgeons worldwide. These procedures are suitable for simulation-based training and should be integrated in the thoracic surgical curriculum.
- 20 February 2023
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 63 (4)
Consensus on technical procedures for simulation-based training in thoracic surgery: an international needs assessment
OBJECTIVES: To identify and prioritize technical procedures for simulation-based training to be integrated into the thoracic surgical curriculum. METHODS: A 3-round Delphi survey was conducted from February 2022 to June 2022 among 34 key opinion leaders in thoracic surgery from 14 countries worldwide. The 1st round was a brainstorming phase to identify technical procedures that a newly qualified thoracic surgeon should be able to perform. All the suggested procedures were categorized, qualitatively analysed and sent to the 2nd round. The second round investigated: the frequency of the identified procedure at each institution, the number of thoracic surgeons that should be able to perform these procedures, the degree of risk to the patient if the procedure is performed by a non-competent thoracic surgeon and the feasibility of simulation-based education. In the 3rd round, elimination and re-ranking of the procedures from the 2nd round were performed. RESULTS: Response rates in the 3 iterative rounds were 80% (28 out of 34), 89% (25 out of 28) and 100% (25 out of 25) in the 1st, 2nd and 3rd round, respectively. Seventeen technical procedures were included for simulation-based training in the final prioritized list. The top 5 procedures were Video-Assisted Thoracoscopic Surgery (VATS) lobectomy, VATS segmentectomy, VATS mediastinal lymph node dissection, diagnostic flexible bronchoscopy and robotic-assisted thoracic surgery port placement, robotic-assisted thoracic surgery docking and undocking. CONCLUSIONS: The prioritized list of procedures represents a consensus of key thoracic surgeons worldwide. These procedures are suitable for simulation-based training and should be integrated in the thoracic surgical curriculum.
- 2 December 2022
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 63 (1)
Real-world postoperative outcomes of segmentectomy versus lobectomy for lung cancer
Christopher Cao, Dominic Gossot, Agathe Seguin-Givelet, Franca Melfi; Real-world postoperative outcomes of segmentectomy versus lobectomy for lung cancer, Europ
- 2 December 2022
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 63 (1)
Real-world postoperative outcomes of segmentectomy versus lobectomy for lung cancer
Christopher Cao, Dominic Gossot, Agathe Seguin-Givelet, Franca Melfi; Real-world postoperative outcomes of segmentectomy versus lobectomy for lung cancer, Europ
- Open Access
- 12 August 2022
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 12 (8) , 1311
Complications of Robotic Video-Assisted Thoracoscopic Surgery Compared to Open Thoracotomy for Resectable Non-Small Cell Lung Cancer
(1) Background: Conventional open thoracotomy has been the accepted surgical treatment for resectable non-small cell lung cancer. However, newer, minimally invasive approaches, such as robotic surgery, have demonstrated similar safety and efficacy with potentially superior peri-operative outcomes. The present study aimed to quantitatively assess these outcomes through a meta-analysis. (2) Methods: A systematic review was performed using electronic databases to identify all of the relevant studies that compared robotic surgery with open thoracotomy for non-small cell lung cancer. Pooled data on the peri-operative outcomes were then meta-analyzed. (3) Results: Twenty-two studies involving 12,061 patients who underwent robotic lung resection and 92,411 patients who underwent open thoracotomy were included for analysis. Mortality rates and length of hospital stay were significantly lower in patients who underwent robotic resection. Compared to open thoracotomy, robotic surgery was also associated with significantly lower rates of overall complications, including atrial arrhythmia, post-operative blood transfusions, pneumonia and atelectasis. However, the operative times were significantly longer with robotic lung resection. (4) Conclusions: The present meta-analysis demonstrated superior post-operative morbidity and mortality outcomes with robotic lung resection compared to open thoracotomy for non-small cell lung cancer.
- 12 August 2022
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 12 (8) , 1311
Open AccessComplications of Robotic Video-Assisted Thoracoscopic Surgery Compared to Open Thoracotomy for Resectable Non-Small Cell Lung Cancer
(1) Background: Conventional open thoracotomy has been the accepted surgical treatment for resectable non-small cell lung cancer. However, newer, minimally invasive approaches, such as robotic surgery, have demonstrated similar safety and efficacy with potentially superior peri-operative outcomes. The present study aimed to quantitatively assess these outcomes through a meta-analysis. (2) Methods: A systematic review was performed using electronic databases to identify all of the relevant studies that compared robotic surgery with open thoracotomy for non-small cell lung cancer. Pooled data on the peri-operative outcomes were then meta-analyzed. (3) Results: Twenty-two studies involving 12,061 patients who underwent robotic lung resection and 92,411 patients who underwent open thoracotomy were included for analysis. Mortality rates and length of hospital stay were significantly lower in patients who underwent robotic resection. Compared to open thoracotomy, robotic surgery was also associated with significantly lower rates of overall complications, including atrial arrhythmia, post-operative blood transfusions, pneumonia and atelectasis. However, the operative times were significantly longer with robotic lung resection. (4) Conclusions: The present meta-analysis demonstrated superior post-operative morbidity and mortality outcomes with robotic lung resection compared to open thoracotomy for non-small cell lung cancer.
- Open Access
- 14 November 2021
- Published by MDPI AG in Current Oncology
- Vol. 28 (6) , 4686-4701
Meta-Analysis of Neoadjuvant Immunotherapy for Patients with Resectable Non-Small Cell Lung Cancer
Purpose: Immunotherapy has created a paradigm shift in the treatment of metastatic non-small cell lung cancer (NSCLC), overcoming the therapeutic plateau previously achieved by systemic chemotherapy. There is growing interest in the utility of immunotherapy for patients with resectable NSCLC in the neoadjuvant setting. The present systematic review and meta-analysis aim to provide an overview of the existing evidence, with a focus on pathological and radiological response, perioperative clinical outcomes, and long-term survival. Methods: A systematic review was conducted using electronic databases from their dates of inception to August 2021. Pooled data on pathological response, radiological response, and perioperative outcomes were meta-analyzed where possible. Results: Eighteen publications from sixteen studies were identified, involving 548 enrolled patients who underwent neoadjuvant immunotherapy, of whom 507 underwent surgery. Pathologically, 52% achieved a major pathological response, 24% a complete pathological response, and 20% reported a complete pathological response of both the primary lesion as well as the sampled lymph nodes. Radiologically, 84% of patients had stable disease or partial response. Mortality within 30 days was 0.6%, and morbidities were reported according to grade and frequency. Conclusion: The present meta-analysis demonstrated that neoadjuvant immunotherapy was feasible and safe based on perioperative clinical data and completion rates of surgery within their intended timeframe. The pathological response after neoadjuvant immunotherapy was superior to historical data for patients who were treated with neoadjuvant chemotherapy alone, whilst surgical and treatment-related adverse events were comparable. The limitations of the study included the heterogenous treatment regimens, lack of long-term follow-up, variations in the reporting of potential prognostic factors, and potential publication bias.
- 14 November 2021
- Published by MDPI AG in Current Oncology
- Vol. 28 (6) , 4686-4701
Open AccessMeta-Analysis of Neoadjuvant Immunotherapy for Patients with Resectable Non-Small Cell Lung Cancer
Purpose: Immunotherapy has created a paradigm shift in the treatment of metastatic non-small cell lung cancer (NSCLC), overcoming the therapeutic plateau previously achieved by systemic chemotherapy. There is growing interest in the utility of immunotherapy for patients with resectable NSCLC in the neoadjuvant setting. The present systematic review and meta-analysis aim to provide an overview of the existing evidence, with a focus on pathological and radiological response, perioperative clinical outcomes, and long-term survival. Methods: A systematic review was conducted using electronic databases from their dates of inception to August 2021. Pooled data on pathological response, radiological response, and perioperative outcomes were meta-analyzed where possible. Results: Eighteen publications from sixteen studies were identified, involving 548 enrolled patients who underwent neoadjuvant immunotherapy, of whom 507 underwent surgery. Pathologically, 52% achieved a major pathological response, 24% a complete pathological response, and 20% reported a complete pathological response of both the primary lesion as well as the sampled lymph nodes. Radiologically, 84% of patients had stable disease or partial response. Mortality within 30 days was 0.6%, and morbidities were reported according to grade and frequency. Conclusion: The present meta-analysis demonstrated that neoadjuvant immunotherapy was feasible and safe based on perioperative clinical data and completion rates of surgery within their intended timeframe. The pathological response after neoadjuvant immunotherapy was superior to historical data for patients who were treated with neoadjuvant chemotherapy alone, whilst surgical and treatment-related adverse events were comparable. The limitations of the study included the heterogenous treatment regimens, lack of long-term follow-up, variations in the reporting of potential prognostic factors, and potential publication bias.
- 12 January 2021
- Published by Elsevier in Seminars in Thoracic and Cardiovascular Surgery
- Vol. 33 (3) , 850-857
Systematic Review of Neoadjuvant Immunotherapy for Patients With Non–Small Cell Lung Cancer
- 12 January 2021
- Published by Elsevier in Seminars in Thoracic and Cardiovascular Surgery
- Vol. 33 (3) , 850-857
Systematic Review of Neoadjuvant Immunotherapy for Patients With Non–Small Cell Lung Cancer
- Open Access
- 1 November 2020
- Published by AME Publishing Company in Annals of Translational Medicine
- Vol. 8 (22) , 1476
Neoadjuvant immunotherapy for patients with non-small cell lung cancer—current evidence
Neoadjuvant immunotherapy for patients with non-small cell lung cancer—current evidence
- 1 November 2020
- Published by AME Publishing Company in Annals of Translational Medicine
- Vol. 8 (22) , 1476
Open AccessNeoadjuvant immunotherapy for patients with non-small cell lung cancer—current evidence
Neoadjuvant immunotherapy for patients with non-small cell lung cancer—current evidence